LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.Leukemia | PMID 40913104PMC12589120 | 2025-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Pridopidine in early-stage manifest Huntington's disease: a phase 3 trial.Nat Med已检查 7 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 other;Fig. 3:森林图/亚组分析图;Fig. 4:AI 判定为 other;Extended Data Fig. 1:AI 判定为 multi panel km;另有 2 张未列出。 | PMID 40913168PMC12618238 | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial.Lancet RheumatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40915298无 PMCID | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial.Nat Med已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:CONSORT/入组流程图;Extended Data Fig. 1:AI 判定为 other;Extended Data Fig. 2:AI 判定为 other。 | PMID 40921806PMC12618248 | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC.Cancer Sci疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:非 KM 图;FIGURE 3:瀑布图;FIGURE 4:非 KM 图;FIGURE 5:非 KM 图。 | PMID 40922529PMC12580869 | 2025-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Long-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4.Diabetes Obes Metab已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other。 | PMID 40926359PMC12515763 | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Temporal Profile of Treatment-Emergent Adverse Events in Adult Asian Patients with Focal-Onset Seizures During Adjunctive Brivaracetam Treatment: Post Hoc Analysis of a Phase 3, Randomized Trial.Adv Ther已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other。 | PMID 40944847PMC12579673 | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of Fimasartan, Atorvastatin, and Ezetimibe Combination Therapy in Patients With Hypertension and Dyslipidemia: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial.Clin TherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40947318无 PMCID | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of DaxibotulinumtoxinA for injection in adults with cervical dystonia: Pooled global analysis of ASPEN-1 and ASPEN-1-CN randomized trials.Parkinsonism Relat DisordPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40961718无 PMCID | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.Lancet Diabetes EndocrinolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40961952无 PMCID | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.Lancet Diabetes EndocrinolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40961953无 PMCID | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial.Cancer Sci | PMID 40976711PMC12580863 | 2025-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Fixed-Dose Brexpiprazole and Sertraline Combination Therapy for the Treatment of Posttraumatic Stress Disorder: A Phase 3, Randomized Trial.J Clin Psychopharmacol已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other。 | PMID 40982703PMC12573675 | 2025 Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Number Needed to Treat and Cost Per Responder Analysis of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in Adults for Whom Prior Preventive Treatments have Failed.Adv Ther已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other;另有 1 张未列出。 | PMID 40986186PMC12579663 | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults.Am J Clin Dermatol已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other。 | PMID 40993471PMC12615541 | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy.Arterioscler Thromb Vasc Biol已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:ROC 图;Figure 2:森林图/亚组分析图;Figure 3:研究设计图。 | PMID 40995631PMC12543001 | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial.Drugs已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 multi panel km;Fig. 3:AI 判定为 forest plot;Fig. 4:AI 判定为 multi panel km;Fig. 5:AI 判定为 forest plot;另有 1 张未列出。 | PMID 41015981PMC12572085 | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Morphine for chronic breathlessness (MABEL) in the UK: a multi-site, parallel-group, dose titration, double-blind, randomised, placebo-controlled trial.Lancet Respir MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41033333无 PMCID | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263).Gynecol Oncol已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1.:CONSORT/入组流程图;Fig. 2.:CONSORT/入组流程图;Fig. 3.:CONSORT/入组流程图;Fig. 4.:AI 判定为 multi panel km。 | PMID 41056581PMC12767459 | 2025-Nov | 0.95 | The study meets the criteria for being an original, randomized, Phase III trial of a drug-containing intervention (chemoradiation vs. radiation) in human oncology. However, it is excluded because the primary and only reported efficacy endpoints are patient-reported quality of life and symptom outcomes, which do not constitute a time-to-event efficacy endpoint as defined by the cohort criteria. | 无 KM 图 |
| Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial.Clin Drug Investig入排复审未纳入:The study is a Phase II randomized trial with drug intervention in oncology, but it is not a definitive Phase III trial, and the primary endpoints are hematologic toxicity measures (neutropenia duration, incidence, ANC nadir/recovery) rather than time-to-event efficacy endpoints like OS or PFS. | PMID 41066031PMC12535520 | 2025-Nov | 0.85 | The study is a Phase II randomized trial with drug intervention in oncology, but it is not a definitive Phase III trial, and the primary endpoints are hematologic toxicity measures (neutropenia duration, incidence, ANC nadir/recovery) rather than time-to-event efficacy endpoints like OS or PFS. | 无 KM 图 |
| Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4·5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trial.Lancet NeurolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41109232无 PMCID | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study.Lancet Neurol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41109234PMC12550255 | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Avelumab Maintenance Therapy in Patients With Curatively Unresectable Urothelial Carcinoma in Japan: Subgroup Analyses of Post-Marketing Surveillance Data by Age, Prior Chemotherapy Regimen, and Best Overall Response to Prior Chemotherapy.Cancer Med入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | PMID 41164972PMC12572950 | 2025-Nov | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Negative hyperselection of patients with stage III colon cancer receiving anti-EGFR-based adjuvant treatment.ESMO Open | PMID 41167084PMC12607000 | 2025-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41167216无 PMCID | 2025-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB-C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial in Sweden.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41167217无 PMCID | 2025-Nov | 0.95 | The record describes a randomized, phase 3 trial with time-to-event efficacy endpoints (OS, DFS) and presents original interim results. However, the intervention is a diagnostic/imaging strategy (CT/PET-CT) added to standard physical examination, not a drug-containing intervention. Therefore, it does not meet the inclusion criterion for a drug-containing intervention. | 无 KM 图 |
| Evaluation of pharmacokinetic interactions between long-acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084.J Int AIDS Soc入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41169120PMC12576019 | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety outcomes among infants whose mothers used the dapivirine vaginal ring or oral PrEP during pregnancy (MTN-042/DELIVER): a randomised phase 3b study.Lancet HIVPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41173578无 PMCID | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Cognitive Function Among Heart Transplant Recipients Before and After Intravenous Iron Supplement for Iron Deficiency: Results From a Randomized, Placebo-Controlled, Double-Blind Treatment Trial.Clin TransplantPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41182019无 PMCID | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study.Target Oncol | PMID 41184595PMC12669286 | 2025-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.Mult Scler入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41190505PMC12589670 | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.Lancet HaematolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41193116无 PMCID | 2025-Nov | 0.45 | The trial is eligible for most criteria (oncology, human, randomized, phase 3, drug intervention, original result), but the required primary/key secondary time-to-event efficacy endpoint is not present. The primary endpoint is a response rate, which is a categorical outcome, not time-to-event. The record's deterministic review correctly identified the lack of a time-to-event signal. | 无 KM 图 |
| Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.Lancet HaematolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41193117无 PMCID | 2025-Nov | 0.95 | This is an original result report from a phase 3 randomized trial of drug-containing interventions in oncology. However, the presented results focus exclusively on patient-reported outcomes (secondary/exploratory endpoints), not the primary or key secondary time-to-event efficacy endpoints (e.g., PFS) which are mentioned in the background but not reported here. The report type is secondary (patient-reported outcomes), not the primary efficacy analysis. | 无 KM 图 |
| Efficacy and Safety of Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis in a China Cohort of a Double-Blind, Randomised, Phase 3 Trial (ReSTORE China).Mycoses已检查 1 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram。 | PMID 41194465PMC12589930 | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Rituximab in New-Onset Generalized Myasthenia Gravis: Long-Term Follow-Up of the RINOMAX Clinical Trial.Eur J Neurol | PMID 41194516PMC12589805 | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Dupilumab efficacy by disease severity in pediatric type 2 asthma.Pediatr Allergy Immunol已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:CONSORT/入组流程图。 | PMID 41200848PMC12593181 | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Exposure-Response Analysis of Donidalorsen for the Treatment of Hereditary Angioedema.Clin Transl Sci疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图;FIGURE 4:AI 判定为 multi panel km;FIGURE 5:非 KM 图;另有 1 张未列出。 | PMID 41208217PMC12597964 | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Historical Control Analysis Demonstrates Greater Long-Term Reduction in Plasma Globotriaosylceramide (Gb3) by Venglustat Compared With Placebo or Agalsidase Beta in Male Patients With Classic Fabry Disease.Mol Genet Genomic Med入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41246852PMC12620990 | 2025-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.ESMO Open | PMID 41320342PMC12684762 | 2025-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor.J Immunother Cancer | PMID 41173494PMC12581073 | 2025-Oct-31 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.Blood | PMID 40737596PMC12824676 | 2025-Oct-30 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40923797无 PMCID | 2025-Oct-30 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4.Eur J Endocrinol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41052284无 PMCID | 2025-Oct-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| One-stage versus two-stage surgery for initially unresectable colorectal cancer liver metastases: post hoc analysis of the CAIRO5 trial.BJS Open入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | PMID 41189486PMC12586848 | 2025-Oct-30 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study.Eur J Med Res疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41163129PMC12573851 | 2025-Oct-29 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8).BMJ | PMID 41224473PMC12570275 | 2025-Oct-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML.Blood Adv | PMID 40706052PMC12550153 | 2025-Oct-28 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants: The Budesonide in Babies (BiB) Randomized Clinical Trial.JAMA已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:森林图/亚组分析图。 | PMID 41026481PMC12486137 | 2025-Oct-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Implementation of the Study Participant Feedback Questionnaire to understand participant experience in a phase 3 oncology clinical trial.BMJ Open已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other。 | PMID 41151963PMC12570934 | 2025-Oct-28 | 0.80 | The record describes a secondary analysis of participant experience in a Phase III randomized oncology trial. While the trial itself is oncology, human, randomized, and Phase III, the specific publication is focused on implementing a feedback questionnaire (quality-of-life/psychosocial measure) and does not report on a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or drug intervention details for this analysis. The deterministic review correctly flagged the absence of a time-to-event signal. | 无 KM 图 |
| Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.Lancet | PMID 41052510PMC12549478 | 2025-Oct-25 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |